Comparison of parameters measured at PRE and INF analysis in both control and hydrocortisone-treated patients
| Patients . | No. . | Blood leukocytes, 109/L . | Blood granulocytes, 109/L . | No. vessels . | Vessel diameter, μm . | Analysis time, s, median (range) . | Leukocyte velocity, μm/s . |
|---|---|---|---|---|---|---|---|
| PRE | |||||||
| Control | 4 | 7.4 ± 1.8 | 4.6 ± 1.1 | 5.5 ± 2.5 | 38.0 ± 9.5 | 67.8 (36-110) | 766.7 ± 144.3 |
| Hydrocortisone | 4 | 7.5 ± 1.1 | 4.6 ± 0.7 | 4.0 ± 1.4 | 38.7 ± 4.9 | 61.3 (54-73) | 822.9 ± 286.8 |
| INF | |||||||
| Control | 4 | 7.4 ± 1.6 | 4.6 ± 0.8 | 3.8 ± 2.2 | 39.9 ± 3.6 | 91.9 (56-121) | 662.5 ± 242.0 |
| Hydrocortisone | 4 | 11.6 ± 2.0 | 7.8 ± 2.0 | 3.8 ± 1.5 | 46.8 ± 10.6 | 107 (36-170) | 763.8 ± 280.2 |
| Patients . | No. . | Blood leukocytes, 109/L . | Blood granulocytes, 109/L . | No. vessels . | Vessel diameter, μm . | Analysis time, s, median (range) . | Leukocyte velocity, μm/s . |
|---|---|---|---|---|---|---|---|
| PRE | |||||||
| Control | 4 | 7.4 ± 1.8 | 4.6 ± 1.1 | 5.5 ± 2.5 | 38.0 ± 9.5 | 67.8 (36-110) | 766.7 ± 144.3 |
| Hydrocortisone | 4 | 7.5 ± 1.1 | 4.6 ± 0.7 | 4.0 ± 1.4 | 38.7 ± 4.9 | 61.3 (54-73) | 822.9 ± 286.8 |
| INF | |||||||
| Control | 4 | 7.4 ± 1.6 | 4.6 ± 0.8 | 3.8 ± 2.2 | 39.9 ± 3.6 | 91.9 (56-121) | 662.5 ± 242.0 |
| Hydrocortisone | 4 | 11.6 ± 2.0 | 7.8 ± 2.0 | 3.8 ± 1.5 | 46.8 ± 10.6 | 107 (36-170) | 763.8 ± 280.2 |
Hemodynamic parameters were measured at each analysis in both patient groups (mean ± SD).